Trial Profile
An Adaptive, Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Orbcel-C (Primary)
- Indications Autoimmune hepatitis; Primary sclerosing cholangitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms MERLIN
- 07 Nov 2022 Planned number of patients changed from 56 to 18.
- 07 Nov 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 07 Nov 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2023.